Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Pretax Margin % : 45.90% (As of Dec. 2023)

View and export this data going back to 2004. Start your Free Trial

What is Clinuvel Pharmaceuticals Pretax Margin %?

Pre-Tax margin is calculated as Pre-Tax Income divided by its Revenue. Clinuvel Pharmaceuticals's Pre-Tax Income for the six months ended in Dec. 2023 was $9.91 Mil. Clinuvel Pharmaceuticals's Revenue for the six months ended in Dec. 2023 was $21.59 Mil. Therefore, Clinuvel Pharmaceuticals's pretax margin for the quarter that ended in Dec. 2023 was 45.90%.

The historical rank and industry rank for Clinuvel Pharmaceuticals's Pretax Margin % or its related term are showing as below:

CLVLF' s Pretax Margin % Range Over the Past 10 Years
Min: -357.62 Med: 46.67 Max: 58.35
Current: 56.37

CLVLF's Pretax Margin % is ranked better than
97.08% of 1027 companies
in the Biotechnology industry
Industry Median: -176.72 vs CLVLF: 56.37

Clinuvel Pharmaceuticals Pretax Margin % Historical Data

The historical data trend for Clinuvel Pharmaceuticals's Pretax Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Clinuvel Pharmaceuticals Pretax Margin % Chart

Clinuvel Pharmaceuticals Annual Data

Trend

Jun14

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Pretax Margin %

Get a 7-Day Free Trial

58.35

40.34

53.59

52.22

58.20

Clinuvel Pharmaceuticals Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
Pretax Margin %	Get a 7-Day Free Trial															35.43	62.29	49.74	63.27	45.90

Competitive Comparison of Clinuvel Pharmaceuticals's Pretax Margin %

For the Biotechnology subindustry, Clinuvel Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Clinuvel Pharmaceuticals's Pretax Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Clinuvel Pharmaceuticals's Pretax Margin % distribution charts can be found below:

* The bar in red indicates where Clinuvel Pharmaceuticals's Pretax Margin % falls into.

Clinuvel Pharmaceuticals Pretax Margin % Calculation

Pretax margin - also known as pretax profit margin is the ratio of Pretax Income divided by net sales or Revenue, usually presented in percent.

Clinuvel Pharmaceuticals's Pretax Margin for the fiscal year that ended in Jun. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (A: Jun. 2023 )	/	Revenue (A: Jun. 2023 )
	=	30.59	/	52.564
	=	58.20 %

Clinuvel Pharmaceuticals's Pretax Margin for the quarter that ended in Dec. 2023 is calculated as

Pretax Margin	=	Pre-Tax Income (Q: Dec. 2023 )	/	Revenue (Q: Dec. 2023 )
	=	9.91	/	21.591
	=	45.90 %

Clinuvel Pharmaceuticals (OTCPK:CLVLF) Pretax Margin % Explanation

The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.

The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.

It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.

The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.

Clinuvel Pharmaceuticals Pretax Margin % Related Terms

Thank you for viewing the detailed overview of Clinuvel Pharmaceuticals's Pretax Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Clinuvel Pharmaceuticals (Clinuvel Pharmaceuticals) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Clinuvel Pharmaceuticals Ltd (OTCPK:CLVLF) » Definitions » Pretax Margin %

Comparable Companies

Traded in Other Exchanges

CLVLY:USA UR9:Germany CUV:Australia

Address

535 Bourke Street, Level 11, Melbourne, VIC, AUS, 3000

Website

https://www.clinuvel.com

Clinuvel distributes a single-product, Scenesse, the only approved treatment for phototoxic reactions specifically associated with a rare genetic disease called erythropoietic protoporphyria. EPP causes extreme pain or burns from brief exposure to light, affecting a patient's quality of life. Scenesse is a patented dissolvable implant, comparable in size with a rice grain, injected underneath the skin roughly every three months for ongoing protection. The implant controls the release of a synthetic drug which promotes the production of more melanin, thereby reducing pain and increasing tolerance for light exposure. The majority of Clinuvel's earnings stem from Europe and the U.S.